New workflow identifies shared cancer targets, advancing immunotherapy

NewsGuard 100/100 Score

In a recent study published in Science Translational Medicine, researchers identify shared immunogenic neoantigens in various cancers using the Splicing Neo Antigen Finder (SNAF) workflow, which integrates deep learning and new algorithms for advancing targeted cancer immunotherapy.

Study: Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. Image Credit: Design_Cells / Shutterstock.com Study: Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. Image Credit: Design_Cells / Shutterstock.com

Background 

The primary aim in cancer treatment is to develop standardized therapies effective for most patients despite the inherent heterogeneity of cancer that often leads to drug resistance and relapse. Recent progress, especially in high-mutation cancers like melanoma, shows promising outcomes with neoantigen-based therapies; however, cancers with low mutation burdens pose challenges for traditional treatments.

Splicing neoantigens, which emerge from posttranscriptional changes, offers new possibilities in cancer targeting. Nevertheless, further research is needed to fully understand and effectively harness the potential of splicing neoantigens for broader and more precise applications in cancer immunotherapy.

About the study 

In the present study, researchers develop a systematic pipeline to identify splicing neoantigens in heterogeneous cancers, focusing on melanoma and ovarian cancer. These cancers were selected for their comprehensive molecular omics datasets, including immunopeptidome and ribonucleic acid sequencing (RNA-Seq) data, diverse therapy regimens, and clinical outcomes.

Bulk long-read RNA-Seq in melanoma cell lines was utilized to capture a broad range of full-length messenger RNA (mRNA) isoforms. The sample size for the bulk RNA-Seq, immunoproteomics, and single-cell RNA sequencing (scRNA-Seq) datasets depended on the original study design.

For in vitro functional validation, neoantigen-major histocompatibility complex

(MHC) binding was confirmed using the transporter associated with antigen processing (TAP)-deficient T2 cell line. The immunogenicity and T-cell reactivity of neoantigens were evaluated using peripheral blood from at least three healthy donors.

SNAF, a modular Python package, was developed to automate splicing neoantigen identification and support both T- and B-cell neoantigen discovery. SNAF includes survival, mass spectrometry (MS) proteomics, and long-read analysis features.

SNAF was used to reanalyze bulk and single-cell RNA-Seq (scRNA-Seq) datasets, focusing on melanoma neoantigens and comparing them to noncancerous skin cells. Thirty-six synthesized neoantigens underwent validation, including MHC-I binding and immunogenicity tests, whereas confocal microscopy confirmed the localization of ExNeoEpitopes. Long-read mRNA isoform sequencing was conducted on melanoma cell lines and aligned with The Cancer Genome Atlas (TCGA) and Van Allen cohort data.

Statistical analyses in the study used a two-sided empirical Bayes moderated t-test for genomic comparative analyses, with false discovery rate adjustments for large datasets. Associations for individual neo-junctions or neoantigens with patient survival were derived using univariate Cox regression analysis.

Study findings 

Two computational workflows were developed to identify and prioritize neoantigens for T- and B-cell-based therapies. SNAF identifies tumor-specific splice junctions and predicts immunogenic neoantigens (SNAF-T) and transmembrane proteins with potential as cancer-specific epitopes (SNAF-B). This approach, using deep learning and probabilistic algorithms, quantifies tumor specificity and immunogenicity of these neoantigens.

The study validated the prediction capabilities of SNAF-T using cancer immunopeptidome datasets, which revealed a higher detection rate of predicted neoantigens as compared to other methods. Seven of the tested neoantigens were validated through mass spectrometry, which indicated the potential of these neoantigens as targets for cancer immunotherapy.

Analysis of splicing neoantigen burden in melanoma patients showed that a high burden correlates with poor overall survival. In contrast, melanoma patients with a high neoantigen burden who received immune checkpoint blockade (ICB) therapy had improved survival, thus suggesting the significance of these neoantigens in predicting treatment response. Differential gene expression analysis revealed that a high neoantigen burden is associated with genes implicated in immune evasion, thus indicating that these patients may benefit from combination therapies.

Shared splicing neoantigens were found in over 15% of patients, thereby indicating their potential as common targets across multiple patients. These shared neoantigens were more frequently detected in independent cohorts and displayed a compositional bias in amino acids, suggesting a broader recognition by various human leukocyte antigen (HLA) genotypes.

The ability of selected shared splicing neoantigens to bind MHC and induce T-cell responses was observed. Furthermore, analysis of scRNA-Seq data showed that these neoantigens are primarily derived from tumor cells rather than the tumor microenvironment.

SNAF-B also successfully predicted full-length mRNAs and stable proteoforms of transmembrane proteins, which could serve as additional targets for therapies like chimeric antigen receptor T-cell therapy (CAR-T) cells or monoclonal antibodies. The study concluded with the development of interactive web applications for exploring and prioritizing predicted neoantigens to ultimately enhance the utility of SNAF in identifying targets for cancer immunotherapy. 

Journal reference:
  • Li, G., Mahajan, S., Ma, S., et al. (2024). Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. Science Translational Medicine. doi:10.1126/scitranslmed.ade2886
Vijay Kumar Malesu

Written by

Vijay Kumar Malesu

Vijay holds a Ph.D. in Biotechnology and possesses a deep passion for microbiology. His academic journey has allowed him to delve deeper into understanding the intricate world of microorganisms. Through his research and studies, he has gained expertise in various aspects of microbiology, which includes microbial genetics, microbial physiology, and microbial ecology. Vijay has six years of scientific research experience at renowned research institutes such as the Indian Council for Agricultural Research and KIIT University. He has worked on diverse projects in microbiology, biopolymers, and drug delivery. His contributions to these areas have provided him with a comprehensive understanding of the subject matter and the ability to tackle complex research challenges.    

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kumar Malesu, Vijay. (2024, January 23). New workflow identifies shared cancer targets, advancing immunotherapy. News-Medical. Retrieved on April 23, 2024 from https://www.news-medical.net/news/20240123/New-workflow-identifies-shared-cancer-targets-advancing-immunotherapy.aspx.

  • MLA

    Kumar Malesu, Vijay. "New workflow identifies shared cancer targets, advancing immunotherapy". News-Medical. 23 April 2024. <https://www.news-medical.net/news/20240123/New-workflow-identifies-shared-cancer-targets-advancing-immunotherapy.aspx>.

  • Chicago

    Kumar Malesu, Vijay. "New workflow identifies shared cancer targets, advancing immunotherapy". News-Medical. https://www.news-medical.net/news/20240123/New-workflow-identifies-shared-cancer-targets-advancing-immunotherapy.aspx. (accessed April 23, 2024).

  • Harvard

    Kumar Malesu, Vijay. 2024. New workflow identifies shared cancer targets, advancing immunotherapy. News-Medical, viewed 23 April 2024, https://www.news-medical.net/news/20240123/New-workflow-identifies-shared-cancer-targets-advancing-immunotherapy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis